SPECTRUM
Spectrum (EudraCT: 2024-520171-27-00) is a multicenter, double-blind, placebo-controlled (two months) clinical trial that aims to study the benefits and safety of a full-spectrum cannabis extract as a treatment for refractory epilepsy associated with Tuberous Sclerosis Complex (TSC), initially in association with pre-existing treatments.